Xi'an Tianlong Science and Technology
Factory area:
Total facility area: 46,500 m², including headquarters, manufacturing and warehousing facilities.
Tianlong Industrial Park: 13,000 m²
Xintai Logistics Park: 20,000 m²
Hanpu Industrial Park: 6,500 m²
Suzhou Plant: 6,000 m²
Wuxi Plant: 1,000 m²
1. Company Overview
Founded in 1997 by Dr. Peng Niancai, a PhD professor at Xi’an Jiaotong University, Xi’an Tianlong Science & Technology Co., Ltd. (Tianlong) specializes in molecular diagnostics and life science technologies.
Over the years, Tianlong has grown into an integrated molecular diagnostics solutions provider, offering a comprehensive portfolio of instruments, reagents, and automated testing systems for clinical diagnostics, animal health, scientific research, food safety, and public health.
Since forming a strategic partnership with KHB in 2018, Tianlong has further expanded its capabilities across biochemistry, immunology, molecular diagnostics, ELISA, and POCT.
2. Corporate History & Group Strength
Tianlong has achieved several important milestones:
1997: Founded in Xi’an, China.
2009: Established Suzhou Tianlong Biotech, focusing on PCR reagent R&D.
2012: Received investment from South Korea's SK Group.
2015: Invested in Wuxi Ruiqi to support personalized medicine development.
2018: Established a strategic partnership with KHB, China's first publicly listed IVD company.
With a history dating back to 1981, KHB has developed five core technology platforms, more than 2,000 employees worldwide, and 37 product subsidiaries.
The group's industrial layout spans Shanghai, Xi’an, Suzhou, the Greater Bay Area, Italy, and South Korea, covering biochemistry, molecular diagnostics, PCR reagents, POCT, CLIA, and mass spectrometry technologies.
3. R&D Capabilities & Innovation
Tianlong has undertaken more than 100 national and provincial research projects in collaboration with leading institutions, including Tsinghua University and the Chinese Academy of Sciences, with total research funding of RMB 202 million (approximately USD 30 million).
Its founder, Dr. Peng Niancai, has been featured on national CCTV channels, and the company's development has received recognition and support from national and provincial government leaders.
In 2020, Tianlong's nucleic acid technology received the National Science and Technology Progress Award, one of China's highest honors for scientific and technological achievements.
4. Products & Solutions
Tianlong offers a comprehensive molecular diagnostics portfolio, including:
20+ types of instruments: Automated nucleic acid extraction systems, real-time PCR systems, and automated sample processing systems.
600+ types of reagents: Covering clinical diagnostics and animal disease testing.
Its solutions support a wide range of applications, including infectious disease detection, blood screening, veterinary diagnostics, food safety, and public health surveillance.
5. Quality Standards & Industry Recognition
Tianlong actively contributes to the development of national and industry standards for nucleic acid extraction kits, extraction instruments, and real-time PCR systems.
The company holds more than 90 medical device registrations in China and 300+ international certifications and regulatory approvals, including CE, FDA-related, and KFDA-related credentials.
Its flagship products, including the GeneRotex 96 Automated Nucleic Acid Extraction System and Gentier 96E Real-Time PCR System, have also been featured on national television.
Tianlong has accumulated more than 100 intellectual property achievements, including invention patents and international awards, alongside numerous national and provincial honors.
6. Global Presence & Partnerships
Tianlong's products are available in more than 100 countries and regions and across over 30 provinces in China.
In China, Tianlong serves approximately 90% of the country's top 10 and top 100 hospitals and has extensive coverage across national and provincial CDC systems.
The company has also established long-term partnerships with internationally recognized institutions and companies, including the University of Utah, Takara (Japan), and Seegene (South Korea).
Its solutions are widely used in clinical diagnostics, forensic testing, scientific research, food safety, animal health, and epidemiological surveillance.
7. Public Health Contributions & Social Responsibility
Tianlong has contributed diagnostic technologies and solutions during major public health events, including SARS, MERS, Ebola, H1N1, African swine fever, COVID-19, and Mpox.
Beyond business development, the company actively fulfills its social responsibilities through voluntary teaching programs, earthquake relief, blood donation campaigns, and support for children with rare diseases.
8. Future Development
Looking ahead, Tianlong will continue to focus on high-throughput molecular diagnostic solutions and portable POCT technologies, strengthening its innovation capabilities and providing efficient, accessible, and reliable diagnostic solutions for global markets.
Driven by innovation and guided by real-world diagnostic needs, Tianlong is committed to advancing molecular diagnostics and supporting global public health.